- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06550141
CAR-T 세포 관련 독성의 Emapalumab 예방
CAR-T 세포 관련 독성 예방을 위한 Emapalumab의 2상 시험
This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).
The research study involves the following study interventions:
- Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
- Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
- Emapalumab
연구 개요
상태
상세 설명
This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.
A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.
The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.
This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.
Once study treatment is completed, the participants will be followed for up to 24 months.
It is expected that about 28 people will take part in this research study.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Matthew Frigault, MD
- 전화번호: (617) 643-6175
- 이메일: MFRIGAULT@partners.org
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital
-
수석 연구원:
- Matthew Frigault, MD
-
연락하다:
- Matthew Frigault, MD
- 전화번호: 617-643-6175
- 이메일: MFRIGAULT@partners.org
-
Boston, Massachusetts, 미국, 02215
- 아직 모집하지 않음
- Dana-Farber Cancer Institute
-
연락하다:
- Caron Jacobson, MD
- 전화번호: (617)-632-5847
- 이메일: Caron_Jacobson@DFCI.HARVARD.EDU
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
-
At least 1 measurable lesion per Lugano at time of screening.
-
Age 18 or older
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- ANC ≥1000/uL
- Platelet count ≥50,000/uL
- Absolute lymphocyte count ≥100/uL
- Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
- Serum ALT/AST ≤2.5 per institutional ULN
- Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
- Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
- Baseline oxygen saturation >92% on room air.
-
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).
-
Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
-
History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.
-
Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.
-
History of allogeneic stem cell transplantation.
-
Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.
-
Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.
- Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
-
No evidence of active CNS disease regardless of prior CNS history.
-
History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.
-
History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.
-
History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.
-
Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.
-
History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.
-
Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T
-
In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
-
History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.
-
Receipt of a BCG vaccine within 12 weeks prior to Screening.
-
Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.
-
Participants who are receiving any other investigational agents for this condition.
-
Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cohort 1a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
다른 이름들:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
실험적: Cohort 1b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
다른 이름들:
Alkylating agent Purine antagonist antimetabolite Autologous treatment Corticosteroid |
|
실험적: Cohort 2a
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Patients will receive emapalumab 3mg/kg on day -1. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. |
An interferon gamma (IFNγ) blocking antibody
다른 이름들:
Alkylating agent Purine antagonist antimetabolite Autologous treatment |
|
실험적: Cohort 2b
Leukapheresis will happen within approximately 5 days of eligibility confirmation. Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours. Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes. Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2. Patients will receive emapalumab 3mg/kg on day +1. |
An interferon gamma (IFNγ) blocking antibody
다른 이름들:
Alkylating agent Purine antagonist antimetabolite Corticosteroid Autologous treatment |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of grade 2+ CRS per ASTCT
기간: Day -1 to 24 months post treatment
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment. |
Day -1 to 24 months post treatment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Rate and severity of ICANS as per ASTCT
기간: 30 days
|
Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion. |
30 days
|
|
Objective response rate (ORR)
기간: Day -1 to 24 months post treatment
|
The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders. |
Day -1 to 24 months post treatment
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Duration of response (DOR)
기간: From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing. |
From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Progression-free Survival (PFS)
기간: From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date. |
From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
|
|
Overall survival (OS)
기간: From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date. |
From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Matthew Frigault, MD, Massachusetts General Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종, B세포
- 림프종
- 헴 및 림프병
- 림프종, 대형 B세포, 미만성
- 림프종, 비호지킨
- 림프종, 여포성
- 아미노산, 펩티드 및 단백질
- 단백질
- 유기 화학 물질
- 탄화수소
- 다 환식 화합물
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 스테로이드, 불소
- 포스 포 아미드 머스타드
- 질소 머스타드 화합물
- 겨자 화합물
- 탄화수소, 할로겐화
- 포스 포 아미드
- 유기 인 화합물
- Pregnadienetriols
- 덱사메타손
- 시클로포스파미드
- 항체, 단클론성
- 플루다 라빈 포스페이트
- alicalabtagene ciloleucel
- Emapalumab
기타 연구 ID 번호
- 24-317
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD 공유 기간
Data can be shared no earlier than 1 year following the date of publication
IPD 공유 액세스 기준
Contact the Partners Innovations team at http://www.partners.org/innovation
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .